Top

Published in:

01-01-2006 | Editorial

Statins: the next step in adjuvant therapy for sepsis?

Authors: Armand Mekontso-Dessap, Christian Brun-Buisson

Published in: Intensive Care Medicine | Issue 1/2006

Excerpt

Statins are powerful hypolipemic drugs with pleiotropic effects and have been shown to improve survival in the primary and secondary prevention of atherosclerosis in numerous large randomized clinical trials [1‐6]. Interestingly, in many of these trials, their beneficial clinical impact included noncoronary events. For example, statin therapy was consistently associated with decreased C-reactive protein (CRP) levels in recent human clinical trials, although the magnitude of this effect varied between drugs [7]. …

Kumana CR, Cheung BM, Lauder IJ (2003) Simvastatin reduced mortality and vascular events in high-risk patients. ACP J Club 138:2–3PubMed

The Scandinavian Simvastatin Survival Study (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344:1383–9PubMed

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349–57CrossRefPubMed

Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22CrossRefPubMed

Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149–1158CrossRefPubMed

Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504CrossRefPubMed

Chan KY, Boucher ES, Gandhi PJ, Silva MA (2004) HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am J Health Syst Pharm 61:1676–1681PubMed

Arnaud C,Mach F (2005) Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. Arch Mal Coeur Vaiss 98:661–666PubMed

Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat MM, Szalai AJ, Princen HM, Kooistra T (2004) Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103:4188–4194CrossRefPubMed

10.

Hernandez-Presa MA, Ortego M, Tunon J, Martin-Ventura JL, Mas S, Blanco-Colio LM, Aparicio C, Ortega L, Gomez-Gerique J, Vivanco F, Egido J (2003) Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 57:168–177CrossRefPubMed

11.

Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, Salmona M (2001) In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 21:1327–1332PubMed

12.

Steiner S, Speidl WS, Pleiner J, Seidinger D, Zorn G, Kaun C, Wojta J, Huber K, Minar E, Wolzt M, Kopp CW (2005) Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111:1841–1846CrossRefPubMed

13.

Krysiak R, Okopien B, Herman Z (2003) Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 63:1821–1854PubMed

14.

Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U, Lin P, Fink LM, Hauer-Jensen M (2003) Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 14:575–585CrossRefPubMed

15.

Pleiner J, Schaller G, Mittermayer F, Zorn S, Marsik C, Polterauer S, Kapiotis S, Wolzt M (2004) Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 110:3349–3354CrossRefPubMed

16.

Giusti-Paiva A, Martinez MR, Felix JV, da Rocha MJ, Carnio EC, Elias LL, Antunes-Rodrigues J (2004) Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock 21:271–275CrossRefPubMed

17.

Wagner AH, Schwabe O, Hecker M (2002) Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol 136:143–149PubMed

18.

Landry DW,Oliver JA (2001) The pathogenesis of vasodilatory shock. N Engl J Med 345:588–595CrossRefPubMed

19.

Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K (2000) Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 294:1043–1046PubMed

20.

Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, Hanrath P, Weber C (2004) HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109:2560–2565CrossRefPubMed

21.

Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, Schrader J, Hanrath P, Weber C (2005) Statin treatment after onset of sepsis in a murine model improves survival. Circulation 112:117–124CrossRefPubMed

22.

Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110:880–885CrossRefPubMed

23.

Liappis AP, Kan VL, Rochester CG, Simon GL (2001) The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33:1352–1357CrossRefPubMed

24.

Fernandez R, De Pedro VJ, Artigas A (2005) Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 2005. DOI: 10.1007/s00134-005-2743-9

25.

Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G (2005) Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2005. DOI: 10.1007/s00134-005-2859-y

Title: Statins: the next step in adjuvant therapy for sepsis?
Authors: Armand Mekontso-Dessap
Christian Brun-Buisson
Publication date: 01-01-2006
Publisher: Springer-Verlag
Published in: Intensive Care Medicine / Issue 1/2006
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-005-2860-5

ACC 2024 Congress

Springer Medicine

Statins: the next step in adjuvant therapy for sepsis?

Excerpt

ACC 2024 Congress

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2006

Echocardiography in the ICU: time for widespread use!

Weaning from mechanical ventilation with pressure support in patients failing a T-tube trial of spontaneous breathing

The intensive care support of patients with malignancy: do everything that can be done

Bedside waveforms interpretation as a tool to identify patient-ventilator asynchronies

Early isovolaemic haemofiltration in oliguric patients with septic shock

Mechanical ventilation for patients with ARDS: a UK survey on calculation of tidal volume